Project Grant R21EY035735
- This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides $450,300 to support research aimed at understanding how corneal limbal stem cells function during wound healing. The project, being conducted by The Regents of the University of California, San Francisco (UCSF), seeks to advance the understanding of limbal stem cell populations and their role in maintaining corneal homeostasis and enabling corneal wound repair. This...
- This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to develop universally immune-compatible induced pluripotent stem cells (iPSCs) for regenerative therapies to treat various eye conditions. The $492,500 award, granted on January 1, 2025, supports research at The Schepens Eye Research Institute, Inc. to generate iPSCs that express peptide-free or low-affinity peptide-loaded HLA-I molecules, protecting them from...
- This Project Grant award of $540,213.00 from the National Eye Institute (CFDA 93.867 - Vision Research) supports research by The Schepens Eye Research Institute, Inc. to investigate the mechanisms by which myofibroblasts regulate effector T cell function and trafficking in corneal transplantation. The research aims to define the precise ways in which myofibroblasts, which are formed during immune rejection, can suppress T cell-mediated alloimmunity and improve corneal transplant survival. This...
- The National Eye Institute (NEI) has awarded a $356,485 Project Grant to Stellular Bio, Inc. under the NEI's Vision Research federal grant program (CFDA 93.867) to support the scale-up and manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjögren's syndrome-related dry eye disease (SSDE). STLR-201 is a platelet and stem cell-based product that promotes corneal epithelial cell proliferation and improves corneal barrier integrity, addressing the critical unmet need for a...
- The National Eye Institute (NEI) awarded a $431,750 Project Grant to the University of California, Irvine (UCI) to support research on "Amplified Femtosecond Laser Permeabilization and Poration for Nonviral Corneal Gene Delivery". The goal is to develop a novel, femtosecond laser-based approach to overcome barriers to topical gene therapy delivery to the cornea. This research aims to create microchannels through the corneal epithelium to enhance transepithelial diffusion and use...
- The National Eye Institute awarded a $615,979 Project Grant to Wayne State University to investigate a peptide-based combination therapy for restoring structure and function in the diabetic cornea. The grant falls under the Vision Research federal grant program (CFDA 93.867), which supports research aimed at understanding, preventing, and treating vision-related conditions and diseases. The primary objectives of this 4-year project are to: 1) establish the therapeutic role of TB4 and VIP as a...
- The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $730,000 Project Grant (CFDA 93.867 - Vision Research) to Human Cell Co, a for-profit biotech firm, to develop an optimized nerve growth factor (NGF) therapy for the treatment of dry eye disease (DED). The funding will support preclinical studies to evaluate the efficacy and mechanism of action of the company's proprietary NGF mutein (HC201) in improving tear film production and corneal...
- This federal Project Grant award of $234,000.00 from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to enhance stem cell restoration of intraocular pressure (IOP) homeostasis through senolytic treatments. The key goals are to study how senescent trabecular meshwork (TM) cells in glaucoma patients affect IOP regulation, and to explore whether clearing these senescent cells using senolytic drugs can improve the effectiveness of...
- This $695,018 federal project grant awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research to define how Müller glia (MG) cells, which function as injury-responsive stem cells, can enable retinal regeneration in zebrafish, mice, and potentially humans. The research aims to identify genes that regulate the regenerative potential of MG cells in the context of selective retinal cell loss, as occurs in degenerative eye diseases. By conducting...
- The National Eye Institute (NEI) awarded a $451,962 Project Grant (CFDA 93.867 Vision Research) to The Regents of the University of California, San Francisco (UCSF) to develop novel mouse models for studying the role of Transcription Factor 4 (TCF4) trinucleotide repeat expansions in the pathogenesis of Fuchs Endothelial Corneal Dystrophy (FECD). The research aims to generate and characterize TCF4 repeat expansion mouse models, as well as to investigate how the TCF4 repeat expansion...
THE ROLE OF LIMBAL FIBROBLASTS FOR THE MAINTENANCE OF LIMBAL STEM CELLS - PROJECT SUMMARY / ABSTRACT CORNEAL EPITHELIUM IS MAINTAINED BY STEM CELLS RESIDING IN THE LIMBUS, THE AREA BETWEEN THE CORNEA AND CONJUNCTIVA. THESE STEM CELLS ARE KNOWN AS LIMBAL STEM CELLS (LSCS) AND GIVE RISE TO PROGENITOR CELLS, WHICH MIGRATE TOWARD CENTRAL AND APICAL CORNEA TO FORM THE STRATIFIED CORNEAL EPITHELIAL CELL LAYERS. LOSS OF LSCS RESULT IN LIMBAL STEM CELL DEFICIENCY (LSCD); THE PATIENTS SUFFER FROM SEVERE VISION LOSS DUE TO THE INGROWTH OF CLOUDY CONJUNCTIVA. WHILE UNILATERAL LSCD CAN BE TREATED BY TRANSPLANTATION OF AUTOLOGOUS LIMBAL TISSUE, PATIENTS WITH BILATERAL LSCD HAVE TO RELY ON ALLOGENEIC TRANSPLANTATION AND THE CLINICAL OUTCOME IS RELATIVELY POOR. IN ADDITION, THERE ARE MULTIPLE POST-OPERATIVE COMPLICATIONS REPORTED INCLUDING RECURRENT/PERSISTENT EPITHELIAL EROSION, INTRAOCULAR PRESSURE ELEVATION, AND REJECTION. MOREOVER, THE SHORTAGE OF CORNEAL DONORS REDUCES THE OPPORTUNITY FOR ALLOGENEIC TRANSPLANTATION. THERE IS, THEREFORE, A CRITICAL NEED TO DEVELOP A LESS INVASIVE THERAPY TO TREAT LSCD THAT ALSO ADDRESSES THE DONOR SHORTAGE. BESIDES THE GRAFT CONDITION, IT IS IMPORTANT TO CONTROL RECIPIENTS' LIMBAL NICHE MICROENVIRONMENT FOR A SUCCESSFUL TRANSPLANTATION, SINCE THERE HAS BEEN GROWING AWARENESS OF THE FACT THAT LIMBAL NICHE CELLS PLAY A CRITICAL ROLE FOR THE MAINTENANCE OF LSCS. OF THE NICHE CELLS, LIMBAL FIBROBLASTS ARE THOUGHT TO CONTRIBUTE TO THE MAINTENANCE OF CORNEAL EPITHELIAL PHENOTYPE BY SECRETING FIBROBLAST GROWTH FACTOR 7 (FGF7), WHOSE SECRETION IS PROMOTED BY PLATELET-DERIVED GROWTH FACTOR (PDGF)-BB AND INTERLEUKIN 1 BETA (IL1B). HOWEVER, IT REMAINS LARGELY UNKNOWN HOW LIMBAL FIBROBLASTS ARE AFFECTED IN THE LSCD AND HOW THE RECOVERY OF LIMBAL FIBROBLASTS CONTRIBUTES TO THE SUCCESS OF THE TREATMENT OF LSCD. OUR LONG-TERM GOAL IS TO DEVELOP A NOVEL TREATMENT FOR LSCD BY RECOVERING THE FUNCTION OF LIMBAL NICHE. OUR OVERALL OBJECTIVE IN THIS PROPOSAL IS TO REVEAL THE CONTRIBUTION OF LIMBAL FIBROBLASTS IN NORMAL AND LSCD CONDITIONS, AND TO ESTABLISH A LIMBAL FIBROBLAST INJECTION AS A NOVEL LSCD THERAPY. OUR CENTRAL HYPOTHESIS IS THAT LIMBAL FIBROBLASTS SECRETE FGF7 IN RESPONSE TO PDGF AND IL1B SECRETED BY LIMBAL DENDRITIC CELLS TO MAINTAIN THE LIMBAL STEM/PROGENITOR CELLS. MOREOVER, WE HYPOTHESIZE THAT LIMBAL NICHE CELLS INCLUDING LIMBAL FIBROBLASTS ARE DISRUPTED IN LSCD AND INJECTION OF LIMBAL FIBROBLASTS REGENERATE THE CORNEAL PHENOTYPE IN LSCD. IN ADDITION, WE WILL UTILIZE A NOVEL TECHNIQUE OF EYE-LIKE ORGANOID FORMATION FROM HUMAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) TO CREATE LIMBAL FIBROBLASTS AS A CELL SOURCE OF INJECTABLE CELLS TO RESOLVE THE CORNEAL DONOR SHORTAGE. PROPOSED STUDY WILL REVEAL THE CHARACTERISTICS OF LIMBAL FIBROBLASTS AND LIMBAL DENDRITIC CELLS (AIM 1), EVALUATE THE INTERACTION OF LIMBAL NICHE CELLS AND LIMBAL EPITHELIAL CELLS (AIM 2), AND ESTABLISH LIMBAL FIBROBLAST INJECTION METHOD FOR THE TREATMENT OF MOUSE LSCD (AIM 3). SUCCESSFUL COMPLETION OF THIS PROJECT WILL IMPROVE OUR UNDERSTANDING OF LIMBAL NICHE CELLS IN NORMAL AND LSCD CONDITIONS, AND PROVIDE US WITH ANOTHER STRATEGIC OPTION TO TREAT LSCD, NAMELY LIMBAL FIBROBLAST INJECTION. THIS WILL ALLOW US TO CONDUCT LARGER ANIMAL EXPERIMENTS AND ULTIMATELY, APPLY THIS TREATMENT TO LSCD PATIENTS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $220.6k | 9/11/25 | ||
| Not listed | $0 | 9/11/25 | ||
| Not listed | $247.5k | 7/25/24 |